BRIEF published on 11/24/2025 at 06:35, 10 months 11 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 10 months 11 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 10 months 11 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 10 months 15 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
BRIEF published on 11/20/2025 at 17:05, 10 months 15 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
PRESS RELEASE published on 11/20/2025 at 17:00, 10 months 15 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF published on 11/20/2025 at 06:35, 10 months 15 days ago Ranibizumab Biosimilar Epruvy® Launched in Germany Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
BRIEF published on 11/20/2025 at 06:35, 10 months 15 days ago Lancement en Allemagne du biosimilaire de ranibizumab Epruvy® Formycon AG Ranibizumab Biosimilaire Lancement En Allemagne Soins Ophtalmiques
PRESS RELEASE published on 11/20/2025 at 06:30, 10 months 15 days ago Ranibizumab Biosimilar Epruvy® launched in Germany Ranibizumab Biosimilar Epruvy® launched in Germany by Formycon AG, Bioeq AG, and Sandoz AG under license agreement, expanding patient access to treatment options for nAMD and retinopathies Formycon AG Germany Ranibizumab Sandoz AG Epruvy
BRIEF published on 11/17/2025 at 06:35, 10 months 18 days ago Formycon franchit une étape importante avec FYB208 pour Dupixent® Maladies Inflammatoires Chroniques Formycon Biosimilaires Dupilumab Preuve Technique De Similitude
Published on 10/05/2026 at 22:30, 1 hour 3 minutes ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 8 hours 48 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 9 hours 3 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 9 hours 3 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 9 hours 33 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/05/2026 at 22:25, 1 hour 8 minutes ago LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 1 hour 28 minutes ago AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 2 hours 23 minutes ago Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 2 hours 28 minutes ago EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 20:15, 3 hours 18 minutes ago EQS-Adhoc: United Internet AG participates in capital increase against contributions in kind at 1&1 AG
Published on 10/05/2026 at 22:12, 1 hour 21 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 1 hour 21 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 5 hours 20 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 5 hours 20 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 5 hours 33 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
